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ABSTRACT
Background. The optimal treatment strategy for elderly
patients with gastric cancer is still controversial. This study
aimed to assess the impact of age on short- and long-term
outcomes after treatment for primary gastric cancer.
Methods. From January 2004 to December 2014, a total of
507 patients underwent gastrectomy for gastric adenocar-
cinoma at two high-volume upper gastrointestinal (GI)
centers. The patients were classified into three groups as
follows: group A (patients B 69 years old, n = 266), group
B (patients 70–79 years old, n = 166), and group C (pa-
tients C 80 years old, n = 75). Clinicopathologic
characteristics as well as, short- and long-term outcomes
were compared between the groups.
Results. The patients in groups B and C had more
comorbidities, whereas the younger subjects (group A) had
more advanced tumor stages. Less extensive surgery was
performed in the groups B and C. Older patients (age
C 70 years) had more postoperative medical complica-
tions. Moreover, group C had a higher postoperative
mortality rate (8.1%) than group A (1.8%) or group B
(1.9%). In the multivariable analysis, age older than
80 years (group C) was a negative independent factor for
overall survival (OS) (hazard ratio [HR], 2.36) compared
with group A, whereas group B seemed to have a compa-
rable risk (HR, 1.37). Notably, the three groups did not
show significant differences in disease-related survival
(DRS).
Conclusion. The data suggest that patients 70–79 years of
age show a risk of postoperative death comparable with
that of younger subjects. However, patients older than
80 years should be carefully selected for surgical treatment
due to the increased risk of postoperative mortality.
As the global population ages, the number of older
patients with gastric cancer increases.1 During the last two
decades, many advances in surgical oncology for the
elderly have been made by improved operative technique
and technology,2,3 greater knowledge of geriatric patho-
physiology, advanced intensive care management, and the
introduction of enhanced recovery programs. Therefore,
old age currently is not considered an absolute con-
traindication to surgery for gastric cancer. Several recent
studies have reported the feasibility of surgery for patients
older than 70 years,4,5 although it still is unclear whether
surgery in octogenarians is safe.6,7
There is a major lack of information for patients age
80 years or older. The most recent studies investigating this
aged population concluded that radical surgery for gastric
cancer in an octogenarian is feasible and effective for
certain subgroups of patients,6 but reported higher mor-
bidity and 90-day mortality rates than for younger
patients.7
To elucidate the best treatment strategy for gastric
cancer in the elderly, this study retrospectively compared
clinicopathologic features, management, postoperative
survival, overall survival, and oncologic outcomes after
gastrectomy at two European upper gastrointestinal (UGI)
cancer centers.
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PATIENTS AND METHODS
All information on patients undergoing gastrectomy for
gastric cancer from January 2004 to December 2014 at two
high-volume UGI centers (the Royal Marsden NHS
Foundation Trust, London [RMH] and Verona University
hospital) was retrospectively recorded from prospectively
collected databases. Cancers of the esophagogastric junc-
tion (Siewert 1 and 2), remnant adenocarcinomas, and non-
adenocarcinoma tumors were excluded.
The type of lymphadenectomy was classified according
to the criteria of the Japanese Gastric Cancer Association.8
Tumor invasion (pT) and lymph node status (pN) followed
the criteria of the International Union Against Cancer
(UICC) TNM Classification of Malignant Tumor, 7th edi-
tion.9 Histologic type was classified as intestinal or diffuse-
mixed in accordance with Lauren’s classification.10
Moreover, the rate of signet ring cell cancer (SRCC)
according to the World Health Organization (WHO) his-
tologic classification also was reported.11
Patients were classified into three groups: group A
(GpA: patients B 69 years old), group B (GpB: patients
70–79 years old), and group C (GpC: patients C 80 years
old). The data were analyzed to identify any differences
between the groups in terms of patient and disease char-
acteristics, treatment strategy, surgical outcome, overall
survival, and oncologic outcome after gastrectomy.
Medical and surgical postoperative complications were
considered separately because they may have not only
different risk factors but also different clinical impacts as
proposed by the Italian Research Group for Gastric Can-
cer.12 Surgical complications were recorded according to
the newly proposed classification,12 whereas ‘‘medical
complications’’ were recorded according to the classifica-
tion of Low et al.13 All the complications also were
classified according to the Clavien-Dindo classification.14
The patients were followed up for 5 years postoperatively.
The survival rate was calculated from the date of the sur-
gery until the date of death or last contact.
Statistical analysis was performed using the Chi square
test for any categorical variables and Levene’s test or
Student’s t test for any continuous variables. Overall sur-
vival (OS) and disease-related survival (DRS) were
calculated using Kaplan-Meier methods, and the signifi-
cance of the test was evaluated using the log-rank test or
the Tarone-Ware test. A multivariable survival analysis
was performed using the Cox proportional hazard method.
A p value lower than 0.05 was considered statistically
significant, and 95% was used as the confidence interval
(CI). The statistical analysis was performed using STATA
13.0 (StataCorp, College Station, TX) Statistics Software.
RESULTS
Clinicopathologic Features and Treatment Strategy
The study investigated 507 patients (266 GpA patients,
166 GpB patients, and 75 GpC patients). As expected, the
GpB and GpC patients had a higher American Society of
Anesthesiology (ASA) score15 (p = 0.001) and a higher
Charlson Comorbidity Index (CCI) 16 (p\ 0.001) than the
younger patients (Table 1). In particular, the incidence of
hypertension and cardiovascular disease was significantly
higher for the patients older than 70 years (p\ 0.001).
The GpA patients were found to have a higher rate of
clinical metastatic disease at diagnosis (9%), a clear
prevalence of SRCC (p\ 0.001), and a more diffuse his-
totype (45%) compared with the two older groups
(Table 1). Considering the pathologic stage (pTNM), GpB
was associated with more stage 2 disease than GpA or GpC
(31.3%), whereas GpA had more advanced and metastatic
disease (16.3%).
The GpA patients received neoadjuvant and periopera-
tive treatments more frequently than the other two groups
(p\ 0.001). No differences were found regarding the tol-
erance for chemotherapy, the completion rate, or the
response to the therapy between the groups (Table 1).
Surgery
The GpC patients underwent a less extensive surgery,
with a higher rate of subtotal gastrectomies (p = 0.03),
despite a comparable tumor distribution and fewer multi-
visceral resections (p = 0.059). Furthermore, the GpB and
GpC patients underwent a less extended lymphadenectomy
(p\ 0.001) than the GpA patients. More than 30% of the
GpA patients underwent an extended lymphadnectomy (D2
plus or more). A standard D2 gastrectomy was performed
for 70% of the GpB patients, whereas almost half of the
octogenarian patients received a D1 lymphadenectomy.
The number of harvested nodes was higher in the GpA
group than in the other groups (p = 0.001). Despite more
limited surgery, the R0 margin rate was comparable
between the groups (Table 2).
Surgical Outcome
The GpA patients were found to have a higher rate of
surgical complications (p = 0.011), whereas the older
patients (GpB and GpC) had more medical complications
(p = 0.021). According to the Clavien-Dindo classifica-
tion,14 the GpA patients had, globally, more major
complications (18%), whereas the GpB patients had more
minor complications (21.6%). Moreover, specifically ana-
lyzing only the major complications, we found that the
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TABLE 1 Clinicopathologic features and treatment strategy
Characteristic GpA GpB GpC p Value
n = 266 (52.5%)
n (%)
n = 166 (32.7%)
n (%)
n = 75 (14.8%)
n (%)
Age (years)
Mean ± SD 56.7 ± 10.2 74.4 ± 2.7 82.8 ± 2.7
Range 27–69 70–79 80–92
Sex 0.000
Female 95 (35.7) 37(22.3%) 38 (50.7)
Male 171 (64.3) 129(77.7%) 37 (49.3)
Comorbidity
Hypertension 50 (24.9) 54 (42.5) 26 (56.5) 0.000
Cardiovascular 40 (19.9) 43 (33.6) 20 (43.5) 0.001
Respiratory 18 (9) 16 (12.6) 6 (13) 0.500
Diabetes 21 (10.4) 21 (16.5) 8 (17.4) 0.200
Renal 7 (3.5) 5 (3.9) 2 (4.3) 0.952
Previous abdominal surgery 21 (10.2) 15 (11.8) 5 (10.9) 0.905
Previous malignancy 25 (12.3) 23 (18) 10 (20.8) 0.199
ASA 0.001
1–2 147 (70.7) 76 (58.5) 20 (40.5)
3–4 61 (29.3) 52 (41.5) 26 (59.5)
Mean CCI 4.8 ± 1.9 6.5 ± 1.2 7.5 ± 1.6 0.000
Location 0.506
Siewert 3 39 (14.8) 29 (17.5) 10 (13.5)
Proximal 25 (9.5) 19 (11.4) 3 (4.1)
Middle 80 (30.3) 43 (25.9) 18 (24.3)
Distal 111 (42) 68 (41) 40 (54.1)
Linitis 9 (3.4) 7 (4.2) 3 (4.1)
cTNM stage 0.052
0 0 (0) 0 (0) 3 (0)
1 52 (22.3) 37 (25.9) 12 (19.4)
2 97 (41.6) 73 (51) 30 (48.4)
3 63 (27) 30 (21) 18 (29)
4 21 (9) 3 (2.1) 2 (3.2)
SRCC 107 (41) 37 (22.7) 18 (24.3) 0.000
Lauren histotype 0.000
Intestinal 107 (43.3) 89 (62.7) 40 (56.3)
Diffuse 113 (45.7) 34 (23.9) 18 (25.4)
Mixed 25 (10.1) 17 (12) 13 (18.3)
pTNM stagea 0.060
1 58 (22) 44 (26.5) 15 (20)
2 60 (22.7) 52 (31.3) 19 (25.3)
3 98 (37.1) 54 (32.5) 33 (44)
4 43 (16.3) 13 (7.8) 8 (10.7)
N status 0.359
N0 102(38.6) 73 (44) 25 (33.3)
N1 32 (12.2) 27 (16.3) 14 (18.7)
N2 41 (15.5) 27 (16.3) 13 (17.3)
N3a 47 (17.8) 21 (12.7) 15 (20)
N3b 42 (15.9) 18 (10.8) 8 (10.7)
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GpA patients had more type 3 complications (21.1%),
whereas the GpB patients had more type 4 complications
(9.4%). The type 3 complications included bleeding,
anastomotic fistula, or intraabdominal abscess and required
surgical, endoscopic, or radiologic intervention. Most of
the type 4 complications comprised severe medical com-
plication such as pneumonia, with respiratory failure or
heart failure. The 30-day mortality rate in the GpC group
TABLE 1 continued
Characteristic GpA GpB GpC p Value
n = 266 (52.5%)
n (%)
n = 166 (32.7%)
n (%)
n = 75 (14.8%)
n (%)
Neodjuvant chemotherapy 117 (44.0) 58 (34.9) 2 (2.7) 0.000
Adjuvant chemotherapy 139 (69.2) 62 (48.8) 4 (10%) 0.000
GpA group A, GpB group B, GpC group C, ASA American Society of Anesthesiology, CCI Charlson Comorbidity Index, cTNM clinical TNM,
pTNM pathologic tumor-node-metastasis, SRCC signet ring cell cancer, SD standard deviation
aSix patients with a complete pathologic response were excluded from the analysis
TABLE 2 Surgery and surgical outcome
Characteristic GpA GpB GpC p Value
n = 266 (52.5%)
n (%)
n = 166 (32.7%)
n (%)
n = 75 (14.8%)
n (%)
Emergency 9 (3.4) 7 (4.2) 4 (5.3) 0.728
Surgery 0.030
TG 124 (46.6) 72 (43.4) 20 (26.7)
STG 132 (49.6) 87 (52.4) 53 (70.7)
PG 10 (3.8) 7 (4.2) 2 (2.7)
Multivisceral resection 58 (21.8) 23 (13.9) 10 (13.3) 0.059
Lymphadenectomy 0.000
D1 38 (15) 28 (18.3) 34 (46.6)
D2 138 (54.5) 108 (70.6) 36 (49.3)
D2? 77 (30.4) 17 (11.1) 3 (4.1)
Surgical margin status 0.096
R0 227 (88) 148 (89.2) 67 (90.5)
R1 23 (8.9) 7 (4.2) 6 (8.1)
R2 8 (3.1) 11 (6.6) 1 (1.4)
Lymph nodes harvested
Median (IQR) 35.7 (7–58) 31.1 (7–58) 28.8 (3–69) 0.001
Complication
Surgical complications 63 (32.5) 23 (19.7) 7 (15.9) 0.011
Medical complications 46 (23.7) 45 (38.5) 14 (31.8) 0.021
Clavien-Dindo (\30 days) 0.419
Minor (1–2) 49 (18.4) 36 (21.6) 11 (14.6)
Major (3– 4–5) 48 (18) 22 (13) 10 (13)
Reoperations 25 (13) 12 (10.3) 3 (6.8) 0.464
Hospital stay
Mean ± SD 16.34 ± 22.1 16.48 ± 16.9 14.4 ± 14.4 0.957
Early mortality
In-hospital mortality 5 (1.9) 3 (1.8) 6 (8.1) 0.010
30-Day mortality 3 (1.1) 3 (1.8) 4 (5.4) 0.064
90-Day mortality 4 (1.5) 3 (1.8) 5 (7.4) 0.009
GpA group A, GpB group B, GpC group C, TG total gastrectomy, STG subtotal gastrectomy, PG partial proximal gastrectomy, IQR interquartile
range, SD standard deviation
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was 5.4% compared with 1.1% in the GpA group and 1.8%
in the GpB group. Moreover, the GpC also had a higher
incidence of 90-day mortality and in-hospital mortality
(8.1%) than the GpA group (1.9%) or the GpB group
(p\ 0.01) (Table 2).
Survival
The survival curves showed no significant difference in
OS (p = 0.107) or DRS (p = 0.319). For the first
18 months after surgery, the mortality rate was the same in
all three groups, but after the second year of follow-up
evaluation, survival differences between the GpC group
and the other two groups became apparent. This difference
may be explained by the greater incidence of non-cancer
deaths in the GpC group (Fig. 1).
A separate survival analysis of the ASA 1–2 and 3–4
subgroups showed no difference between the age classes in
terms of low comorbidity patients (p = 0.907). On the
other hand, in the ASA 3–4 patients, the oldest group, had a
5-year OS of 16% (95% CI, 4–35%), which was signifi-
cantly lower (p = 0.024) than that of the young (GpA)
patients (38%; 95% CI, 25–51%) or the elderly (GpB)
patients (48%; 95% CI, 32–62%). (Fig 2).
Multivariable Analysis
The three groups were analyzed for potential significant
confounding factors stratified for disease stage (pTNM).
The findings showed ASA (1–2 vs 3–4), tumor location,
type of surgery, multivisceral resections, presence of
SRCC, Laurèn histotype, and surgical margin positivity to
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FIG. 1 a Overall survival curves according to the three groups
(Young = Gp A; Elderly = Gp B; Oldest = Gp C). Tarone-Ware
test = 4.46, p = 0.107. b Disease related survival curves according to
the three groups (Young = Gp A; Elderly = Gp B; Oldest = Gp C).





































FIG. 2 a Overall Survival curves according to the three groups
(Young = Gp A; Elderly = Gp B; Oldest = Gp C) in patients ASA
1-2. Log-rank test = 0.19, p = 0.907. b Overall Survival curves
according to the three groups (Young = Gp A; Elderly = Gp B;
Oldest = Gp C) in patients ASA 3–4. Log-rank test = 7.45, p = 0.024
2378 V. Mengardo et al.
A multivariable analysis including age and the other sig-
nificant confounding factors showed that age older than
80 years is an independent prognostic factor for OS (hazard
ratio [HR], 2.22; 95% CI, 1.36–3.63). Comparison of GpB
and GpC showed a borderline significant difference in OS
(p = 0.0615). Other significant independent prognostic factors
were presence of ASA 3–4, tumor location, diffuse Lauren
histotype, and residual disease after surgery (Table 3).
The same analysis performed for DRS found that the
presence of ASA 3–4 and residual disease after surgery
were significant in the Cox multivariable analysis. Com-
parison of the three groups showed that age is not a
significant prognostic factor for DRS (p = 0.491)
(Table 4). The Shoenfeld residual test confirmed the Cox
model proportional hazards assumption of both multivari-
able analyses.
TABLE 3 Uni- and
multivariable overall survival
(OS) analyses stratified by
pathologic tumor-node-
metastasis (pTNM)
Univariable analysis Multivariable analysis
OS v2 p Value HR (95% CI) p Value
Sex (male/female) 0.01 0.925
Aging group 4.46 0.107
GpA 1 (ref)
GpB 1.358 (0.919–2.008) 0.124
GpC 2.223 (1.361–3.630) 0.001
ASA (1–2/3–4) 4.51 0.034 1.448 (1.005–2.087) 0.046
Location 22.64 0.000
Siewert 3 1 (ref)
Fundus 0.599 (0.323–1.110) 0.104
Body 0.301 (0.167–0.542) 0.000
Antrum 0.766 (0.399–1.470) 0.424
Linites 0.425 (0.180–1.002) 0.051
NCT (no/yes) 0.41 0.520
Type of operation 20.93 0.000
TG 1 (ref)
STG 0.590 (0.352–0.991) 0.046





ACT (no/yes) 0.32 0.573
Multivisceral resections (no/yes) 16.82 0.000 1.101 (0.717–1.689) 0.658
Complications (CD 0–1–2/3–4–5) 3.26 0.071
Surgical complications (no/yes) 1.20 0.272
Medical complications (no/yes) 2.66 0.103
SRCC (no/yes) 7.22 0.007 1.012 (0.656–1.559) 0.956
Lauren histotype 17.44 0.000
Intestinal 1 (ref)
Diffuse 1.630 (1.010–2.631) 0.045
Mixed 1.029 (0.602–1.758) 0.915
Surgical margin status 214.52 0.000
R0 1 (ref)
R1 3.643 (2.048–7.478) 0.000
R2 5.531 (2.366–12.930) 0.000
Aging group sub-analysis: GpC vs GpB (p = 0.0615)
HR hazard ratio, CI confidence interval, GpA group A, GpB group B, GpC group C, ref reference category,
ASA American Society of Anesthesiology, NCT neoadjuvant chemotherapy, TG total gastrectomy, STG
subtotal gastrectomy, PG partial proximal gastrectomy, ACT adjuvant chemotherapy, CD Clavien-Dindo
classification, SRCC signet ring cell cancer
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DISCUSSION
With a global increase in aging, as described by the
United Nations 2015 report, surgical oncology faces new
management challenges. Octogenarians are predicted to
form more than 20% of the world’s population in 2050
compared with 14% in 2015.17 The treatment strategy for
gastric cancer in the elderly has changed over the decades,
and progressive improvements in surgical and anaesthetic
techniques have led to a decrease in postoperative mortality
rates,2 and higher resection rates have been reported.3
Although many authors have reported in the last 10 years
that surgery for the elderly is feasible and safe,4,5 the rec-
ommended treatment for the elderly patient still is debated.
TABLE 4 Uni- and
multivariable disease-related
survival analyses stratified by
pathologic tumor-node-
metastasis (pTNM)
Univariable analysis Multivariable analysis
DRS v2 p Value HR (95% CI) p Value
Sex (male/female) 0.82 0.365
Aging group 2.29 0.318
GpA 1 (ref)
GpB 0.908 (0.523–1.579) 0.735
GpC 1.214 (0.585–2.519) 0.601
ASA (1–2/3–4) 5.02 0.025 1.717 (1.060–2.781) 0.028
Location 16.91 0.002
Siewert 3 1 (ref)
Fundus 0.469 (0.185–1.190) 0.111
Body 0.521 (0.249–1.089) 0.083
Antrum 0.743 (0.319–1.729) 0.491
Linites 0.484 (0.175–1.339) 0.163
NCT (no/yes) 0.46 0.498
Type of operation 18.52 0.000
TG 1 (ref)
STG 0.606 (0.317–1.158) 0.130
PG 0.579 (0.108–3.100) 0.524
Lymphadenectomy 6.00 0.049
D1 1 (ref)
D2 0.918 (0.503–1.672) 0.780
D2? 0.608 (0.283–1.306) 0.203
ACT (no/yes) 0.18 0.673
Multivisceral resections (no/yes) 16.14 0.000 0.815 (0.464–1.431) 0.477
Complications (CD 0–1–2/3–4–5) 3.87 0.049 0.910 (0.525–1.579) 0.739
Surgical complications (no/yes) 2.44 0.118
Medical complications (no/yes) 1.97 0.160
SRCC (no/yes) 10.40 0.001 0.948 (0.552–1.627) 0.847
Lauren histotype 23.59 0.000
Intestinal 1 (ref)
Diffuse 1.670 (0.903–3.086) 0.102
Mixed 1.080 (0.490–2.383) 0.847
Surgical margin status 252.11 0.000
R0 1 (ref)
R1 3.955 (1.990–7.863) 0.000
R2 6.266 (1.520–25.818) 0.011
Aging group subanalysis: GpC vs GpB (p = 0.491)
DRS disease-related survival, HR hazard ratio, CI confidence interval, GpA group A, GpB group B, GpC
group C, ASA American Society of Anesthesiology, NCT neoadjuvant chemotherapy, TG total gastrectomy,
STG subtotal gastrectomy, PG partial proximal gastrectomy, ACT adjuvant chemotherapy, CD Clavien-
Dindo classification, SRCC signet ring cell cancer
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According to a general consensus in the literature, aging
itself should not be considered as a major risk factor for
surgery. The major concern and selection criteria for any
oncologic treatment is frailty of the patient. Frailty iden-
tifies the recognized medical syndrome of decreased
physiologic reserve,18 a condition that results from the
effect of comorbidities.
As expected, in this study, the patients older than
70 years had a higher ASA and a higher CCI rate than the
younger patients. Nevertheless, the patients younger than
69 years presented with more advanced and aggressive
disease in terms of staging and histologic features, with a
high rate of SRCC, a diffuse histotype, and more metastatic
disease at surgery. This is not discordant with the standard
profile described in the literature.
In elderly patients, gastric cancer frequently is located in
the proximal stomach, with an intestinal histotype and a
tendency to be well-differentiated,3 and the estimated
percentage of SRCC is lower.19 The less advanced disease
at diagnosis in the elderly might be explained by a less
aggressive cancer behavior,20 but because the current study
was a surgical series, these findings may have been the
result of a selection bias by the surgeons. Indeed, surgeons
often avoid performing major surgery for high-risk patients
in the setting of advanced disease.
In this study, elderly patients underwent less extensive
surgery at the expense of a compromised lymphadenec-
tomy, especially octogenarian patients, half of whom
underwent a D1 dissection. For these reasons, younger
patients were susceptible to a higher rate of surgical
complications, particularly Clavien-Dindo grade 3 com-
plications that required surgical, endoscopic, or radiologic
intervention. In contrast, the presence of medical comor-
bidities in the older groups could explain the increased
Clavien-Dindo grade 2 complications managed with phar-
macologic treatments.
Similar results have been reported by other authors,
although few have considered octogenarian patients.21–23
Takama et al.24 compared the outcomes between patients
older than 70 years and patients older than 80 years. The
findings showed a similar incidence of complications.
These authors suggested that less extensive surgery should
be preferred for patients older than 80 years.
Other studies have described a high rate of morbidity
and mortality after surgery. Hayashi et al.25 reported that
the general morbidity rate after D2 or modified D2 lym-
phadenectomy was acceptable at 18%, but that severe
complications were more frequent (16%) among the
elderly, suggesting that surgery for gastric cancer in
patients older than 80 years has risks and should be limited.
Recently, Ruspi et al.26 reviewed seven studies focused
on morbidity and mortality to determine the role of lym-
phadenectomy for gastric cancer in elderly patients. They
concluded that a standard D2 lymphadenectomy is safe,
conferring an oncologic benefit in overall survival for fit
elderly patients as well as young patients. This advantage is
lost for high-risk elderly patients, resulting in more post-
operative complications. For these patients, a limited
lymphadenectomy would be a better option. Many other
authors conclude the same, suggesting that less aggressive
surgery should be the most appropriate treatment for
patients older than 80 years.4,5
With regard to survival outcomes, the current study
showed significant differences in overall survival between
the groups classified according to age but no differences in
the oncologic outcomes in terms of DRS. These results
were concordant not only with the results of studies
investigating patients older than 70 years,5,6,27 but also
with the findings specifically for patients older than
80 years.5,7,22,28–31 In the current study, ASA score, and
not ageing, was a prognostic factor in DRS. This could be
explained by the difficulty in actively treating patients with
high comorbidity in favor of palliative treatments. How-
ever, the similar rates of DRS support active cancer
treatment for those elderly patients with good performance
status and minimal comorbidity.
Many physicians specializing in care of the elderly
currently are emphasizing that the optimal surgical man-
agement for elderly patients should start preoperatively. In
a recent article, Parks et al.32 describes how patients older
than 80 years are complex and need specific assessments.
These authors have proposed that to improve the current
care of elderly patients, a multidisciplinary team should
include a geriatrician dedicated to preoperative assessment
and optimization followed by postoperative involvement in
patient recovery.
CONCLUSION
Currently, patients 70–79 years old should be consid-
ered as having a risk comparable with that of younger
patients and patients older than 80 years as having a higher
risk. Despite this, radical surgery for some octogenarian
patients fit for surgery is feasible and oncologically justi-
fied by good long-term outcomes in terms of OS and DRS.
The majority of patients older than 80 years will not be in
this category, however, and for these patients, a less
aggressive approach is appropriate.
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